KRAS mutant harboring (KRAS-MUT) non-small cell lung cancer (NSCLC) also has integrin β3-NRP1-KRAS-MUT ternary complex and the downstream signaling of PI3K-AKT signaling leading to primary resistance in vitro and in vivo mouse models. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.